ALNYLAM PHARMACEUTICALS INC (ALNY)
US02043Q1076 - Common Stock
| 2023 (2023-12-31) | 2022 (2022-12-31) | 2021 (2021-12-31) | 2020 (2020-12-31) | 2019 (2019-12-31) | ||||
|---|---|---|---|---|---|---|---|---|
| CASH FLOWS FROM OPERATING ACTIVITIES | ||||||||
| Net Income | -440.24M | -1.13B | -852.80M | -858.30M | -886.10M | |||
| Depreciation Amortization | 54.05M | 44.50M | 47.60M | 34.80M | 17.20M | |||
| Change In Working Capital | 10.76M | -35.60M | -162.80M | -12.70M | 402.40M | |||
| Interest Paid | 32.12M | 45.20M | 24.70M | N/A | 200.00K | |||
| Taxes Paid | N/A | N/A | N/A | N/A | 2.60M | |||
| Other non cash items | 479.58M | 581.00M | 326.40M | 221.20M | 188.10M | |||
| OPERATING CASH FLOW | 104.16M | -541.30M | -641.70M | -615.00M | -278.40M | |||
| CASH FLOWS FROM INVESTING ACTIVITIES | ||||||||
| Capital Expenditure | -62.21M | -72.10M | -76.40M | -70.40M | -140.20M | |||
| Other Investing Activity | -274.14M | 241.40M | -196.90M | -365.20M | -277.50M | |||
| INVESTING CASH FLOW | -336.35M | 169.40M | -273.30M | -435.50M | -417.70M | |||
| CASH FLOWS FROM FINANCING ACTIVITIES | ||||||||
| Debt Issued/Reduced | 0.00 | 135.40M | 500.00M | 200.00M | -30.00M | |||
| Stock Issued/Repurchased | 147.46M | 259.40M | 246.30M | 300.00M | 853.20M | |||
| Other Financing Activity | 24.67M | 31.00M | 500.90M | 495.00M | N/A | |||
| FINANCING CASH FLOW | 172.13M | 425.80M | 1.25B | 995.00M | 823.20M | |||
| Exchange Rate Effect | 6.39M | -7.40M | -9.00M | 4.90M | -100.00K | |||
| CHANGE IN CASH | -53.67M | 46.50M | 323.10M | -50.60M | 127.00M | |||
| FREE CASH FLOW | ||||||||
| Operating Cash Flow | 104.16M | -541.30M | -641.70M | -615.00M | -278.40M | |||
| Capital Expenditure | -62.21M | -72.10M | -76.40M | -70.40M | -140.20M | |||
| FREE CASH FLOW | 41.95M | -613.40M | -718.10M | -685.40M | -418.60M | |||
All data in USD